ERBB2 and lobular breast carcinoma in situ: Higher expression was associated with non-TNBC status, with ER and PR positivity and HER2 negativity, presence of ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), lack of lymphovascular invasion (LVI) and lower Ki67 proliferation index.